319 related articles for article (PubMed ID: 22379899)
1. [Morphological characteristics and prognostic criteria for gastrointestinal stromal tumors].
Tsyganova IV; Anurova OA; Mazurenko NN
Arkh Patol; 2011; 73(6):37-42. PubMed ID: 22379899
[TBL] [Abstract][Full Text] [Related]
2. The GIST paradigm: how to establish diagnostic and prognostic criteria.
Calabuig-Farinas S; Lopez-Guerrero JA; Llombart-Bosch A
Arkh Patol; 2011; 73(4):13-21. PubMed ID: 22164425
[TBL] [Abstract][Full Text] [Related]
3. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
López RL; del Muro XG
Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
[TBL] [Abstract][Full Text] [Related]
4. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
5. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
[TBL] [Abstract][Full Text] [Related]
6. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
[TBL] [Abstract][Full Text] [Related]
7. Patient with high-risk GIST not associated with c-KIT mutations: same benefit from adjuvant therapy?
Izquierdo ME; Bonastre MT
Anticancer Drugs; 2012 Jun; 23 Suppl():S7-9. PubMed ID: 22739668
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
Miettinen M; Sobin LH; Lasota J
Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
[TBL] [Abstract][Full Text] [Related]
10. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.
Gronchi A
Eur J Cancer; 2013 Mar; 49(4):884-92. PubMed ID: 23206668
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection.
Rutkowski P; Wozniak A; Dębiec-Rychter M; Kąkol M; Dziewirski W; Zdzienicki M; Ptaszynski K; Jurkowska M; Limon J; Siedlecki JA
Cancer; 2011 Nov; 117(21):4916-24. PubMed ID: 21456019
[TBL] [Abstract][Full Text] [Related]
12. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).
Dematteo RP; Gold JS; Saran L; Gönen M; Liau KH; Maki RG; Singer S; Besmer P; Brennan MF; Antonescu CR
Cancer; 2008 Feb; 112(3):608-15. PubMed ID: 18076015
[TBL] [Abstract][Full Text] [Related]
13. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
[TBL] [Abstract][Full Text] [Related]
14. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.
Rutkowski P; Bylina E; Wozniak A; Nowecki ZI; Osuch C; Matlok M; Switaj T; Michej W; Wroński M; Głuszek S; Kroc J; Nasierowska-Guttmejer A; Joensuu H
Eur J Surg Oncol; 2011 Oct; 37(10):890-6. PubMed ID: 21737227
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal stromal tumors (GISTs): a pathology view point.
Sornmayura P
J Med Assoc Thai; 2009 Jan; 92(1):124-35. PubMed ID: 19260254
[TBL] [Abstract][Full Text] [Related]
16. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
[TBL] [Abstract][Full Text] [Related]
17. [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)].
Des Guetz G; De Mestier P; Pierga JY
J Chir (Paris); 2002 Oct; 139(5):268-73. PubMed ID: 12410126
[TBL] [Abstract][Full Text] [Related]
18. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).
Martín J; Poveda A; Llombart-Bosch A; Ramos R; López-Guerrero JA; García del Muro J; Maurel J; Calabuig S; Gutierrez A; González de Sande JL; Martínez J; De Juan A; Laínez N; Losa F; Alija V; Escudero P; Casado A; García P; Blanco R; Buesa JM;
J Clin Oncol; 2005 Sep; 23(25):6190-8. PubMed ID: 16135486
[TBL] [Abstract][Full Text] [Related]
19. Imatinib (Glivec) and gastrointestinal stromal tumours in Nigerians.
Durosinmi MA; Salawu L; Lawal OO; Ojo OS; Alatishe OI; Oyekunle AA; Bolarinwa RA; Adisa AO; Badmos K; Anomneze EE; Ayansanwo AO
Afr J Med Med Sci; 2013 Dec; 42(4):325-32. PubMed ID: 24839736
[TBL] [Abstract][Full Text] [Related]
20. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
